The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Open accessAbstract
Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with several sGC agonists currently in clinical development. On binding of NO to a prosthetic heme group on sGC, the enzyme catalyzes synthesis of the second messenger cGMP, which produces vasorelaxation and inhibits smooth muscle proliferation, leukocyte recruitment, and platelet aggregation through a number of downstream mechanisms.1,2 Impaired NO and cGMP signaling has been implicated in the pathogenesis of cardiovascular disease, including systemic arterial and pulmonary hypertension (PH), coronary artery disease, peripheral vascular disease (including erectile dysfunction), and atherosclerosis.1,3,–,5 Organic nitrates that target the NO signaling pathway have been used to treat cardiovascular disease for >150 years. More recently, gaseous NO administered by inhalation has been approved for the treatment of persistent PH of the newborn.3,6 These agents nonetheless have several important limitations. Cardiovascular disease is associated with resistance to NO and organic nitrates.7 This may be due to the oxidative stress–induced alteration of the redox state of the prosthetic heme on sGC (from ferrous to ferric) that weakens the binding of heme to the enzyme and renders sGC unresponsive to NO.1,8 Furthermore, the long-term efficacy of organic nitrates is limited by the development of tolerance.9 Nitric oxide may also have numerous cytotoxic effects, mostly attributed to the reactive oxidant peroxynitrite (formed from the diffusion-controlled reaction of NO with superoxide).3,10 Peroxynitrite interacts with proteins and lipids, altering cellular signaling, disrupting mitochondrial function, and damaging DNA, which can eventually culminate in cellular dysfunction and/or death.3 Because the beneficial effects of NO appear to be …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Self-citation2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Pathophysiology of coronary artery disease
Libby, P., & Theroux, P. (2005) · Circulation · doi:10.1161/circulationaha.105.537878 · Cited by 1,965
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P., & Stewart, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282402 · Cited by 1,842
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Cited by
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H.-A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,401
Vericiguat in patients with heart failure and reduced ejection fraction
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915928 · Cited by 1,358
Riociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Pulmonary Hypertension Due to Left Heart Diseases
Vachiéry, J.-L., Adir, Y., Barberà, J. A., Champion, H., Coghlan, J. G., Cottin, V., De Marco, T., Galiè, N., Ghio, S., Gibbs, J. S. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.033 · Cited by 636
Strategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F., & Schulz, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008300 · Cited by 562
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Epidemiology and treatment of pulmonary arterial hypertension
Lau, E. M. T., Giannoulatou, E., Celermajer, D. S., & Humbert, M. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.84 · Cited by 507
Pulmonary Hypertension Due to Left Heart Disease
Guazzi, M., & Borlaug, B. A. (2012) · Circulation · doi:10.1161/circulationaha.111.085761 · Cited by 483
PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery
Andersson, K. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14205 · Cited by 445
Management of Pulmonary Arterial Hypertension
McLaughlin, V. V., Shah, S. J., Souza, R., & Humbert, M. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.540 · Cited by 366
Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
Humbert, M., Lau, E. M. T., Montani, D., Jaïs, X., Sitbon, O., & Simonneau, G. (2014) · Circulation · doi:10.1161/circulationaha.114.006974 · Cited by 342
Bonderman, D., Ghio, S., Felix, S. B., Ghofrani, H.-A., Michelakis, E., Mitrovic, V., Oudiz, R. J., Boateng, F., Scalise, A.-V., Roessig, L., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001458 · Cited by 326
The Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Consortium, Lu, X., Wang, L., Chen, S., He, L., Yang, X., Shi, Y., Cheng, J., Zhang, L., Gu, C. C., et al. (2012) · Nature Genetics · doi:10.1038/ng.2337 · Cited by 319
Simonneau, G., D’Armini, A. M., Ghofrani, H.-A., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Wang, C., Wilkins, M. R., Fritsch, A., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00087114 · Cited by 315
Novel roles of cAMP/cGMP‐dependent signaling in platelets
SMOLENSKI, A. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04576.x · Cited by 312
Armstrong, P. W., Lam, C. S. P., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., O’Connor, C. M., Pieske, B., Ponikowski, P., Shah, S. J., Solomon, S. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.15922 · Cited by 293
Varga, Z. V., Giricz, Z., Liaudet, L., Haskó, G., Ferdinandy, P., & Pacher, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.030 · Cited by 286
Self-citationDysfunctional nitric oxide signalling increases risk of myocardial infarction
CARDIoGRAM, Erdmann, J., Stark, K., Esslinger, U. B., Rumpf, P. M., Koesling, D., de Wit, C., Kaiser, F. J., Braunholz, D., Medack, A., et al. (2013) · Nature · doi:10.1038/nature12722 · Cited by 284
Daiber, A., Di Lisa, F., Oelze, M., Kröller‐Schön, S., Steven, S., Schulz, E., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13403 · Cited by 269
Bonderman, D., Pretsch, I., Steringer-Mascherbauer, R., Jansa, P., Rosenkranz, S., Tufaro, C., Bojic, A., Lam, C. S. P., Frey, R., Ochan Kilama, M., et al. (2014) · Chest · doi:10.1378/chest.14-0106 · Cited by 260
Brownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators
Follmann, M., Griebenow, N., Hahn, M. G., Hartung, I., Mais, F., Mittendorf, J., Schäfer, M., Schirok, H., Stasch, J., Stoll, F., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302588 · Cited by 200
Self-citationDessauer, C. W., Watts, V. J., Ostrom, R. S., Conti, M., Dove, S., & Seifert, R. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013078 · Cited by 201
Vita, J. A. (2011) · Circulation · doi:10.1161/circulationaha.111.078824 · Cited by 195
Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling
Rahaman, M. M., Nguyen, A. T., Miller, M. P., Hahn, S. A., Sparacino-Watkins, C., Jobbagy, S., Carew, N. T., Cantu-Medellin, N., Wood, K. C., Baty, C. J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310705 · Cited by 92
Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm
Martin, E., Golunski, E., Laing, S. T., Estrera, A. L., & Sharina, I. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00222.2014 · Cited by 23
Sharina, I. G., & Martin, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6687 · Cited by 19
Ghosh, A., & Stuehr, D. J. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6690 · Cited by 19
Metadata
- Authors
- Stasch, J.-P., Pacher, P., & Evgenov, O. V.
- Venue
- Circulation
- Published
- 2011-05-24
- Volume
- 123
- Issue
- 20
- Pages
- 2263-2273
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2090159456
- Cited by
- 601
- References
- 126
- FWCI
- 29.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.